PureTech Health plc PRTC.L Stock
PureTech Health plc Price Chart
PureTech Health plc PRTC.L Financial and Trading Overview
PureTech Health plc stock price | 214.5 GBP |
Previous Close | 232 GBP |
Open | 229 GBP |
Bid | 235.5 GBP x 0 |
Ask | 236 GBP x 0 |
Day's Range | 229 - 238 GBP |
52 Week Range | 145.8 - 300 GBP |
Volume | 18.98K GBP |
Avg. Volume | 215.78K GBP |
Market Cap | 662.94M GBP |
Beta (5Y Monthly) | 0.79157 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.14 GBP |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.85 GBP |
PRTC.L Valuation Measures
Enterprise Value | 356.53M GBP |
Trailing P/E | N/A |
Forward P/E | -4.916667 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 42.446907 |
Price/Book (mrq) | 121.274414 |
Enterprise Value/Revenue | 22.828 |
Enterprise Value/EBITDA | -1.857 |
Trading Information
PureTech Health plc Stock Price History
Beta (5Y Monthly) | 0.79157 |
52-Week Change | 59.21% |
S&P500 52-Week Change | 20.43% |
52 Week High | 300 GBP |
52 Week Low | 145.8 GBP |
50-Day Moving Average | 219.04 GBP |
200-Day Moving Average | 238.52 GBP |
PRTC.L Share Statistics
Avg. Volume (3 month) | 215.78K GBP |
Avg. Daily Volume (10-Days) | 242.11K GBP |
Shares Outstanding | 277.29M |
Float | 155.32M |
Short Ratio | N/A |
% Held by Insiders | 15.51% |
% Held by Institutions | 72.79% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -1266.52% |
Gross Margin | 100.00% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -14.99% |
Return on Equity (ttm) | -6.55% |
Income Statement
Revenue (ttm) | 15.62M GBP |
Revenue Per Share (ttm) | 0.06 GBP |
Quarterly Revenue Growth (yoy) | -25.69% |
Gross Profit (ttm) | N/A |
EBITDA | -191960000 GBP |
Net Income Avi to Common (ttm) | -50354000 GBP |
Diluted EPS (ttm) | -0.14 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 350.1M GBP |
Total Cash Per Share (mrq) | 1.26 GBP |
Total Debt (mrq) | 46.87M GBP |
Total Debt/Equity (mrq) | 8.56 GBP |
Current Ratio (mrq) | 3.986 |
Book Value Per Share (mrq) | 1.946 |
Cash Flow Statement
Operating Cash Flow (ttm) | -178792000 GBP |
Levered Free Cash Flow (ttm) | -236954368 GBP |
Profile of PureTech Health plc
Country | United Kingdom |
State | MA |
City | Boston |
Address | 6 Tide Street |
ZIP | 02210 |
Phone | 617 482 2333 |
Website | https://www.puretechhealth.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 111 |
PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Q&A For PureTech Health plc Stock
What is a current PRTC.L stock price?
PureTech Health plc PRTC.L stock price today per share is 214.5 GBP.
How to purchase PureTech Health plc stock?
You can buy PRTC.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for PureTech Health plc?
The stock symbol or ticker of PureTech Health plc is PRTC.L.
Which industry does the PureTech Health plc company belong to?
The PureTech Health plc industry is Biotechnology.
How many shares does PureTech Health plc have in circulation?
The max supply of PureTech Health plc shares is 2.7M.
What is PureTech Health plc Price to Earnings Ratio (PE Ratio)?
PureTech Health plc PE Ratio is now.
What was PureTech Health plc earnings per share over the trailing 12 months (TTM)?
PureTech Health plc EPS is -0.14 GBP over the trailing 12 months.
Which sector does the PureTech Health plc company belong to?
The PureTech Health plc sector is Healthcare.
PureTech Health plc PRTC.L included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
FTSE 250 FTMC | 19721.24 GBP 25222.2 USD |
-0.33
|
— — | 19720.23 GBP 25220.91 USD | 19990.54 GBP 25566.62 USD | — - | — — |
UK FTSE All Share FTAS | 4353.66 GBP 5568.05 USD |
+0.72
|
— — | 4322.37 GBP 5528.03 USD | 4382.9 GBP 5605.45 USD | — - | — — |
FTSE 350 FTLC | 4398.53 GBP 5625.44 USD |
+0.73
|
— — | 4366.53 GBP 5584.51 USD | 4428.44 GBP 5663.69 USD | — - | — — |
- {{ link.label }} {{link}}